FGFR2 and infantile convulsions and choreoathetosis: In this sense, four phase II clinical trials have already described the benefit of FGFR2-directed therapies in patients with iCCA harboring FGFR2 alterations who progressed under first line treatment with the standard of care (gemcitabine-cisplatin), reporting promising results.